CAR-T's Third Wave: Bio-O-Sigma Pioneers Innovative Technology to Enable Global Pharmaceutical Companies
Within a few months, the in vivo CAR-T therapy has repeatedly sparked industry events. AbbVie acquired Capstan Therapeutics for $21 billion in cash, gaining its first-in-class anti-CD19 in vivo CAR-T